Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery
Dewald C, Becker L, Maschke S, Meine T, Alten T, Kirstein M, Vogel A, Wacker F, Meyer B, Hinrichs J. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clinical & Experimental Metastasis 2020, 37: 683-692. PMID: 33034815, PMCID: PMC7666275, DOI: 10.1007/s10585-020-10057-9.Peer-Reviewed Original ResearchConceptsCommon Terminology Criteria for Adverse EventsPost-procedural adverse eventsCS-PHPAdverse eventsOverall survivalUveal melanomaTherapy responseHepatic perfusionLiver surgeryLiver metastases of uveal melanomaPercutaneous isolated hepatic perfusionMatched groupMetastases of uveal melanomaSeverity of adverse eventsAEs grade 3Percutaneous hepatic perfusionPeri-procedural safetyHigh tumor burdenMetastatic uveal melanomaPeri-procedural complicationsResponse to treatmentMann-Whitney U testKaplan-Meier estimatesRight hemihepatectomyWilcoxon signed-rank
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply